1
|
Li X, Xiu X, Su R, Ma S, Li Z, Zhang L, Wang Z, Zhu Y, Ma F. Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery. NANOTECHNOLOGY 2024; 35:125101. [PMID: 38100843 DOI: 10.1088/1361-6528/ad1644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Accepted: 12/15/2023] [Indexed: 12/17/2023]
Abstract
Mucosal delivery systems have gained much attention as effective way for antigen delivery that induces both systemic and mucosal immunity. However, mucosal vaccination faces the challenges of mucus barrier and effective antigen uptake and presentation. In particular, split, subunit and recombinant protein vaccines that do not have an intact pathogen structure lack the efficiency to stimulate mucosal immunity. In this study, poly (lactic acid-co-glycolic acid-polyethylene glycol) (PLGA-PEG) block copolymers were modified by mannose to form a PLGA-PEG-Man conjugate (mannose modified PLGA-PEG), which were characterized. The novel nanoparticles (NPs) prepared with this material had a particle size of about 150 nm and a zeta potential of -15 mV, and possessed ideal mucus permeability, immune cell targeting, stability and low toxicity. Finally, PLGA-PEG-Man nanoparticles (PLGA-PEG-Man NPs) were successfully applied for intranasal delivery of split influenza vaccine in rat for the first time, which triggered strong systemic and mucosal immune responses. These studies suggest that PLGA-PEG-Man NPs could function as competitive potential nano-adjuvants to address the challenge of inefficient mucosal delivery of non-allopathogenic antigens.
Collapse
Affiliation(s)
- Xuemei Li
- Laboratory of Biologics and Biomaterials, College of Pharmacy, Zhejiang University of Technology, Deqing 313216, People's Republic of China
| | - Xueliang Xiu
- Laboratory of Biologics and Biomaterials, College of Pharmacy, Zhejiang University of Technology, Deqing 313216, People's Republic of China
| | - Rui Su
- Laboratory of Biologics and Biomaterials, College of Pharmacy, Zhejiang University of Technology, Deqing 313216, People's Republic of China
| | - Shichao Ma
- Laboratory of Biologics and Biomaterials, College of Pharmacy, Zhejiang University of Technology, Deqing 313216, People's Republic of China
| | - Zhipeng Li
- Laboratory of Biologics and Biomaterials, College of Pharmacy, Zhejiang University of Technology, Deqing 313216, People's Republic of China
| | - Li Zhang
- Laboratory of Biologics and Biomaterials, College of Pharmacy, Zhejiang University of Technology, Deqing 313216, People's Republic of China
| | - Zhi Wang
- Center for Electron Microscopy, Institute for Frontier and Interdisciplinary Sciences; and State Key Laboratory Breeding Base of Green Chemistry Synthesis Technology, College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China
| | - Yihan Zhu
- Center for Electron Microscopy, Institute for Frontier and Interdisciplinary Sciences; and State Key Laboratory Breeding Base of Green Chemistry Synthesis Technology, College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China
| | - Fengsen Ma
- Laboratory of Biologics and Biomaterials, College of Pharmacy, Zhejiang University of Technology, Deqing 313216, People's Republic of China
- Micro-nano Scale Biomedical Engineering Laboratory, Institute for Frontiers and Interdisciplinary Sciences, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China
- Zhejiang Provincial Key Laboratory of Quantum Precision Measurement, Hangzhou 310023, People's Republic of China
| |
Collapse
|
2
|
Effah F, Adragna J, Luglio D, Bailey A, Marczylo T, Gordon T. Toxicological assessment of E-cigarette flavored E-liquids aerosols using Calu-3 cells: A 3D lung model approach. Toxicology 2023; 500:153683. [PMID: 38013136 PMCID: PMC10826471 DOI: 10.1016/j.tox.2023.153683] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 11/19/2023] [Accepted: 11/22/2023] [Indexed: 11/29/2023]
Abstract
Scientific progress and ethical considerations are increasingly shifting the toxicological focus from in vivo animal models to in vitro studies utilizing physiologically relevant cell cultures. Consequently, we evaluated and validated a three-dimensional (3D) model of the human lung using Calu-3 cells cultured at an air-liquid interface (ALI) for 28 days. Assessment of seven essential genes of differentiation and transepithelial electrical resistance (TEER) measurements, in conjunction with mucin (MUC5AC) staining, validated the model. We observed a time-dependent increase in TEER, genetic markers of mucus-producing cells (muc5ac, muc5b), basal cells (trp63), ciliated cells (foxj1), and tight junctions (tjp1). A decrease in basal cell marker krt5 levels was observed. Subsequently, we utilized this validated ALI-cultured Calu-3 model to investigate the adversity of the aerosols generated from three flavored electronic cigarette (EC) e-liquids: cinnamon, vanilla tobacco, and hazelnut. These aerosols were compared against traditional cigarette smoke (3R4F) to assess their relative toxicity. The aerosols generated from PG/VG vehicle control, hazelnut and cinnamon e-liquids, but not vanilla tobacco, significantly decreased TEER and increased lactate dehydrogenase (LDH) release compared to the incubator and air-only controls. Compared to 3R4F, there were no significant differences in TEER or LDH with the tested flavored EC aerosols other than vanilla tobacco. This starkly contrasted our expectations, given the common perception of e-liquids as a safer alternative to cigarettes. Our study suggests that these results depend on flavor type. Therefore, we strongly advocate for further research, increased user awareness regarding flavors in ECs, and rigorous regulatory scrutiny to protect public health.
Collapse
Affiliation(s)
- Felix Effah
- Pharmacology Section, St George's University of London, Cranmer Terrace, SW17 0RE London, UK; UK Health Security Agency, Radiation, Chemical and Environmental Hazards, Chilton, Didcot, Oxfordshire OX11 ORQ, UK.
| | - John Adragna
- Division of Environmental Medicine, New York University Langone Health, New York, NY, USA
| | - David Luglio
- Division of Environmental Medicine, New York University Langone Health, New York, NY, USA
| | - Alexis Bailey
- Pharmacology Section, St George's University of London, Cranmer Terrace, SW17 0RE London, UK
| | - Tim Marczylo
- UK Health Security Agency, Radiation, Chemical and Environmental Hazards, Chilton, Didcot, Oxfordshire OX11 ORQ, UK
| | - Terry Gordon
- Division of Environmental Medicine, New York University Langone Health, New York, NY, USA
| |
Collapse
|
3
|
Józsa L, Nemes D, Pető Á, Kósa D, Révész R, Bácskay I, Haimhoffer Á, Vasvári G. Recent Options and Techniques to Assess Improved Bioavailability: In Vitro and Ex Vivo Methods. Pharmaceutics 2023; 15:pharmaceutics15041146. [PMID: 37111632 PMCID: PMC10144798 DOI: 10.3390/pharmaceutics15041146] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 03/28/2023] [Accepted: 03/31/2023] [Indexed: 04/08/2023] Open
Abstract
Bioavailability assessment in the development phase of a drug product is vital to reveal the disadvantageous properties of the substance and the possible technological interventions. However, in vivo pharmacokinetic studies provide strong evidence for drug approval applications. Human and animal studies must be designed on the basis of preliminary biorelevant experiments in vitro and ex vivo. In this article, the authors have reviewed the recent methods and techniques from the last decade that are in use for assessing the bioavailability of drug molecules and the effects of technological modifications and drug delivery systems. Four main administration routes were selected: oral, transdermal, ocular, and nasal or inhalation. Three levels of methodologies were screened for each category: in vitro techniques with artificial membranes; cell culture, including monocultures and co-cultures; and finally, experiments where tissue or organ samples were used. Reproducibility, predictability, and level of acceptance by the regulatory organizations are summarized for the readers.
Collapse
Affiliation(s)
- Liza Józsa
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
| | - Dániel Nemes
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
| | - Ágota Pető
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
| | - Dóra Kósa
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
| | - Réka Révész
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
| | - Ildikó Bácskay
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
- Institute of Healthcare Industry, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
| | - Ádám Haimhoffer
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
| | - Gábor Vasvári
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary
| |
Collapse
|